TECLens and SERVImed Industrial have entered into a partnership aimed at developing a combination product to treat keratoconus, according to a press release.
The product will consist of TECLens’ CXLens cross-linking system for corneal remodeling and SERVImed’s transepithelial Ribocross riboflavin formulation, the release said.
“The combination of SERVImed’s proven Ribocross and TECLens’ proven CXLens will provide patients with a comfortable, noninvasive alternative to the treatment of ectatic disorders. Unlike any other cross-linking system, CXLens can treat both eyes simultaneously. Our combination product with Ribocross will significantly increase clinical efficiency and procedure margin for physicians practicing corneal cross-linking,” David Acker, CEO of TECLens, said in the release.
The companies will pursue FDA approval of the product. Ribocross has an FDA orphan drug designation for keratoconus treatment in patients undergoing corneal cross-linking.